Bank of America’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-274,164
| Closed | -$1.24M | – | 8728 |
|
|
2025
Q2 | $1.24M | Sell |
274,164
-8,154
| -3% | -$36.6K | ﹤0.01% | 5151 |
|
|
2025
Q1 | $1.25M | Buy |
282,318
+155,159
| +122% | +$901K | ﹤0.01% | 5067 |
|
|
2024
Q4 | $996K | Buy |
127,159
+47,439
| +60% | +$578K | ﹤0.01% | 5036 |
|
|
2024
Q3 | $1.05M | Buy |
79,720
+35,037
| +78% | +$444K | ﹤0.01% | 5032 |
|
|
2024
Q2 | $540K | Buy |
44,683
+31,546
| +240% | +$426K | ﹤0.01% | 5294 |
|
|
2024
Q1 | $214K | Sell |
13,137
-23,376
| -64% | -$315K | ﹤0.01% | 5851 |
|
|
2023
Q4 | $249K | Buy |
36,513
+2,077
| +6% | +$12K | ﹤0.01% | 5957 |
|
|
2023
Q3 | $188K | Sell |
34,436
-1,280
| -4% | -$7.45K | ﹤0.01% | 5931 |
|
|
2023
Q2 | $243K | Sell |
35,716
-49,739
| -58% | -$373K | ﹤0.01% | 5715 |
|
|
2023
Q1 | $428K | Buy |
85,455
+62,332
| +270% | +$255K | ﹤0.01% | 5476 |
|
|
2022
Q4 | $113K | Sell |
23,123
-80,463
| -78% | -$585K | ﹤0.01% | 6185 |
|
|
2022
Q3 | $1.49M | Buy |
103,586
+34,679
| +50% | +$574K | ﹤0.01% | 4547 |
|
|
2022
Q2 | $1.04M | Sell |
68,907
-329,916
| -83% | -$3.85M | ﹤0.01% | 4875 |
|
|
2022
Q1 | $4.74M | Buy |
398,823
+316,898
| +387% | +$3.25M | ﹤0.01% | 3696 |
|
|
2021
Q4 | $1.33M | Buy |
81,925
+1,661
| +2% | +$35.5K | ﹤0.01% | 4976 |
|
|
2021
Q3 | $2.29M | Sell |
80,264
-2,306
| -3% | -$72.7K | ﹤0.01% | 4318 |
|
|
2021
Q2 | $2.79M | Buy |
82,570
+2
| +0% | +$64 | ﹤0.01% | 4046 |
|
|
2021
Q1 | $2.5M | Buy |
82,568
+21,801
| +36% | +$894K | ﹤0.01% | 4063 |
|
|
2020
Q4 | $3.01M | Sell |
60,767
-11,403
| -16% | -$527K | ﹤0.01% | 3592 |
|
|
2020
Q3 | $2.77M | Buy |
72,170
+2,859
| +4% | +$114K | ﹤0.01% | 3425 |
|
|
2020
Q2 | $2.99M | Buy |
69,311
+1,714
| +3% | +$64.8K | ﹤0.01% | 3305 |
|
|
2020
Q1 | $1.76M | Sell |
67,597
-18,785
| -22% | -$545K | ﹤0.01% | 3576 |
|
|
2019
Q4 | $2.7M | Buy |
86,382
+27,538
| +47% | +$815K | ﹤0.01% | 3784 |
|
|
2019
Q3 | $1.53M | Buy |
58,844
+39,586
| +206% | +$1.01M | ﹤0.01% | 4253 |
|
|
2019
Q2 | $441K | Buy |
19,258
+7,054
| +58% | +$162K | ﹤0.01% | 5151 |
|
|
2019
Q1 | $321K | Buy |
12,204
+6,175
| +102% | +$136K | ﹤0.01% | 5272 |
|
|
2018
Q4 | $122K | Buy |
6,029
+5,838
| +3,057% | +$134K | ﹤0.01% | 5807 |
|
|
2018
Q3 | $5K | Buy |
+191
| New | +$4.86K | ﹤0.01% | 6841 |
|
Other funds holding YMAB
Bank of America's YMAB Position: Q3 2025 in Review
Bank of America sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 274,164 shares — an estimated $1.24M sold.
Bank of America first reported a position in YMAB in Q3 2018 and held it in 28 quarters. The position peaked at $4.74M in Q1 2022. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Bank of America reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Bank of America sold 274,164 Y-mAbs Therapeutics shares in Q3 2025, an estimated $1.24M.
- Bank of America first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 28 quarters.
- Bank of America's Y-mAbs Therapeutics position peaked at $4.74M in Q1 2022.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Bank of America's 13F filing for Q3 2025, filed 14 Nov 2025.